Skip to main content

Advertisement

SpringerLink
Log in

Is transketolase like 1 a target for the treatment of differentiated thyroid carcinoma? A study on thyroid cancer cell lines

  • PRECLINICAL STUDIES
  • Published:
Investigational New Drugs Aims and scope Submit manuscript

Summary

Radioactive iodine-refractory [18F] fluorodeoxy-glucose-positron emission tomography-positive thyroid carcinomas represent especially aggressive tumors. Targeting glucose metabolism by the transketolase isoenzyme transketolase like 1 (TKTL-1) which is over-expressed in various neoplasms, may be effective. The correlation of TKTL-1 expression and the response to oxythiamine as the currently best-characterized inhibitor of transketolases was studied in differentiated thyroid cancer cell lines. We determined TKTL-1 expression, proliferation, glucose uptake and GLUT-1 expression in non-treated thyroid cells and recorded the effect of oxythiamine on iodide uptake and on thymidine uptake. TKTL 1 was highest expressed in cell lines derived from more invasive tumors but the expression level was not strongly correlated to proliferation rate, to GLUT-1 expression or to the response to oxythiamine. Oxythiamine showed only a weak effect in the TKTL-1 expressing cell lines. Over-expression of TKTL-1 is not an indicator for responsiveness to oxythiamine. More specific inhibitors should be tested.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Pacini F (2008) Where Do We Stand with Targeted Therapy of Refractory Thyroid Cancer?-Utility of RECIST Criteria. Thyroid 18:279–280. doi:10.1089/thy.2008.0038

    Article  PubMed  Google Scholar 

  2. Rivera M, Ghossein RA, Schoder H et al (2008) Histopathologic characterization of radioactive iodine-refractory fluorodeoxyglucose-positron emission tomography-positive thyroid carcinoma. Cancer 113(1):48–56

    Article  PubMed  Google Scholar 

  3. Langbein S, Zerilli M, Zur Hausen A et al (2006) Expression of transketolase TKTL1 predicts colon and urothelial cancer patient survival: Warburg effect reinterpreted. Br J Cancer 94:578–585. doi:10.1038/sj.bjc.6602962

    Article  PubMed  CAS  Google Scholar 

  4. Volker HU, Scheich M, Schmausser B et al (2007) Overexpression of transketolase TKTL1 is associated with shorter survival in laryngeal squamous cell carcinomas. Eur Arch Otorhinolaryngol 264:1431–1436. doi:10.1007/s00405-007-0394-x

    Article  PubMed  Google Scholar 

  5. Foldi M, Stickeler E, Bau L et al (2007) Transketolase protein TKTL1 overexpression: A potential biomarker and therapeutic target in breast cancer. Oncol Rep 17:841–845

    PubMed  Google Scholar 

  6. Zhang S, Yang JH, Guo CK et al (2007) Gene silencing of TKTL1 by RNAi inhibits cell proliferation in human hepatoma cells. Cancer Lett 253:108–114. doi:10.1016/j.canlet.2007.01.010

    Article  PubMed  CAS  Google Scholar 

  7. Reske SN, Kotzerke J (2001) FDG-PET for clinical use. Results of the 3rd German Interdisciplinary Consensus Conference, “Onko-PET III”, 21 July and 19 September 2000. Eur J Nucl Med 28:1707–1723. doi:10.1007/s002590100626

    Article  PubMed  CAS  Google Scholar 

  8. Nelson D, Cox M (2004) Lehninger: Principles of Biochemistry, 4th edn. Freeman, New York

    Google Scholar 

  9. Singh D, Banerji AK, Dwarakanath BS et al (2005) Optimizing cancer radiotherapy with 2-deoxy-d-glucose dose escalation studies in patients with glioblastoma multiforme. Strahlenther Onkol 181:507–514. doi:10.1007/s00066-005-1320-z

    Article  PubMed  Google Scholar 

  10. Herrera MF, Hay ID, Wu PS et al (1992) Hurthle cell (oxyphilic) papillary thyroid carcinoma: a variant with more aggressive biologic behavior. World J Surg 16:669–674 discussion 774–665 doi:10.1007/BF02067351

    Article  PubMed  CAS  Google Scholar 

  11. Wahl R, Brossart P, Eizenberger D et al (1992) Direct effects of protirelin (TRH) on cultured porcine thyrocytes. J Endocrinol Invest 15:345–351

    PubMed  CAS  Google Scholar 

  12. Hu LH, Yang JH, Zhang DT et al (2007) The TKTL1 gene influences total transketolase activity and cell proliferation in human colon cancer LoVo cells. Anticancer Drugs 18:427–433. doi:10.1097/CAD.0b013e328013d99e

    Article  PubMed  CAS  Google Scholar 

  13. Marchesi M, Biffoni M, Biancari F et al (2003) Predictors of outcome for patients with differentiated and aggressive thyroid carcinoma. Eur J Surg Suppl 588:46–50

    PubMed  Google Scholar 

  14. Savagner F, Franc B, Guyetant S et al (2001) Defective mitochondrial ATP synthesis in oxyphilic thyroid tumors. J Clin Endocrinol Metab 86:4920–4925. doi:10.1210/jc.86.10.4920

    Article  PubMed  CAS  Google Scholar 

  15. Langbein S, Frederiks WM, zur Hausen A et al (2008) Metastasis is promoted by a bioenergetic switch: new targets for progressive renal cell cancer. Int J Cancer 122:2422–2428. doi:10.1002/ijc.23403

    Article  PubMed  CAS  Google Scholar 

  16. Evans A, Bates V, Troy H et al (2008) Glut-1 as a therapeutic target: increased chemoresistance and HIF-1-independent link with cell turnover is revealed through COMPARE analysis and metabolomic studies. Cancer Chemother Pharmacol 61:377–393. doi:10.1007/s00280-007-0480-1

    Article  PubMed  CAS  Google Scholar 

  17. Pelicano H, Martin DS, Xu RH et al (2006) Glycolysis inhibition for anticancer treatment. Oncogene 25:4633–4646. doi:10.1038/sj.onc.1209597

    Article  PubMed  CAS  Google Scholar 

  18. Nagamatsu S, Nakamichi Y, Inoue N et al (1996) Rat C6 glioma cell growth is related to glucose transport and metabolism. Biochem J 319(Pt 2):477–482

    PubMed  CAS  Google Scholar 

  19. Smith TA, Titley JC, McCready VR (1998) Proliferation is associated with 2-deoxy-D-[1-3H]glucose uptake by T47D breast tumour and SW480 and SW620 colonic tumour cells. Nucl Med Biol 25:481–485. doi:10.1016/S0969-8051(98)00014-6

    Article  PubMed  CAS  Google Scholar 

  20. Higashi K, Clavo AC, Wahl RL (1993) Does FDG uptake measure proliferative activity of human cancer cells? In vitro comparison with DNA flow cytometry and tritiated thymidine uptake. J Nucl Med 34:414–419

    PubMed  CAS  Google Scholar 

  21. Effert P, Beniers AJ, Tamimi Y et al (2004) Expression of glucose transporter 1 (Glut-1) in cell lines and clinical specimens from human prostate adenocarcinoma. Anticancer Res 24:3057–3063

    PubMed  CAS  Google Scholar 

  22. Rastogi S, Banerjee S, Chellappan S et al (2007) Glut-1 antibodies induce growth arrest and apoptosis in human cancer cell lines. Cancer Lett 257:244–251. doi:10.1016/j.canlet.2007.07.021

    Article  PubMed  CAS  Google Scholar 

  23. Yamada K, Brink I, Bisse E et al (2005) Factors influencing [F-18] 2-fluoro-2-deoxy-D-glucose (F-18 FDG) uptake in melanoma cells: the role of proliferation rate, viability, glucose transporter expression and hexokinase activity. J Dermatol 32:316–334

    PubMed  CAS  Google Scholar 

  24. Kurokawa T, Yoshida Y, Kawahara K et al (2004) Expression of GLUT-1 glucose transfer, cellular proliferation activity and grade of tumor correlate with [F-18]-fluorodeoxyglucose uptake by positron emission tomography in epithelial tumors of the ovary. Int J Cancer 109:926–932. doi:10.1002/ijc.20057

    Article  PubMed  CAS  Google Scholar 

  25. Boros LG, Brandes JL, Yusuf FI et al (1998) Inhibition of the oxidative and nonoxidative pentose phosphate pathways by somatostatin: a possible mechanism of antitumor action. Med Hypotheses 50:501–506. doi:10.1016/S0306-9877(98)90271-7

    Article  PubMed  CAS  Google Scholar 

  26. Rais B, Comin B, Puigjaner J et al (1999) Oxythiamine and dehydroepiandrosterone induce a G1 phase cycle arrest in Ehrlich’s tumor cells through inhibition of the pentose cycle. FEBS Lett 456:113–118. doi:10.1016/S0014-5793(99)00924-2

    Article  PubMed  CAS  Google Scholar 

  27. Strumilo SA, Senkevich SB, Vinogradov VV (1984) Effect of oxythiamine on adrenal thiamine pyrophosphate-dependent enzyme activities. Biomed Biochim Acta 43:159–163

    PubMed  CAS  Google Scholar 

  28. Brin M (1962) Effects of thiamine deficiency and of oxythiamine on rat tissue transketolase. J Nutr 78:179–183

    PubMed  CAS  Google Scholar 

  29. Coy JF, Dressler D, Wilde J et al (2005) Mutations in the transketolase-like gene TKTL1: clinical implications for neurodegenerative diseases, diabetes and cancer. Clin Lab (Zaragoza) 51:257–273

    CAS  Google Scholar 

  30. Strumilo SA, Senkevich SB, Galitskii EA et al (1983) Enzyme activity of thiamine pyrophosphate in the rat after oxythiamine administration. Biull Eksp Biol Med 96:42–44

    PubMed  CAS  Google Scholar 

  31. Le Huerou Y, Gunawardana I, Thomas AA et al (2008) Prodrug thiamine analogs as inhibitors of the enzyme transketolase. Bioorg Med Chem Lett 18:505–508. doi:10.1016/j.bmcl.2007.11.100

    Article  PubMed  Google Scholar 

  32. Shreve DS, Holloway MP, Haggerty JC 3rd et al (1983) The catalytic mechanism of transketolase. Thiamin pyrophosphate-derived transition states for transketolase and pyruvate dehydrogenase are not identical. J Biol Chem 258:12405–12408

    PubMed  CAS  Google Scholar 

  33. Coy JF, Dubel S, Kioschis P et al (1996) Molecular cloning of tissue-specific transcripts of a transketolase-related gene: implications for the evolution of new vertebrate genes. Genomics 32:309–316. doi:10.1006/geno.1996.0124

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgements

The excellent technical help of Mrs Elke Maier is gratefully acknowledged.

Author information

Authors and Affiliations

  1. Department of Endocrinology, Metabolism, Nephrology and Clinical Chemistry, Internal Medicine, University of Tuebingen, Otfried-Muellerstrasse 10, 72076, Tuebingen, Germany

    Eleonore Fröhlich, Inge Fink & Richard Wahl

  2. Department IV, Internal Medicine, University of Tuebingen, Otfried Muellerstr. 10, 72076, Tuebingen, Germany

    Richard Wahl

Authors
  1. Eleonore Fröhlich
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Inge Fink
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Richard Wahl
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Richard Wahl.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Fröhlich, E., Fink, I. & Wahl, R. Is transketolase like 1 a target for the treatment of differentiated thyroid carcinoma? A study on thyroid cancer cell lines. Invest New Drugs 27, 297–303 (2009). https://doi.org/10.1007/s10637-008-9174-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10637-008-9174-8

Keywords

Search

Navigation